only a minor role to the metabolism of cediranib. In conclusion, species differences in the formation of the N + -glucuronide metabolite of cediranib were observed. All other metabolites of cediranib found in humans were also detected in rat and cynomolgus monkey.
Non-CYP450 enzymes are predominantly involved in the metabolism of cediranib and this suggests that clinical drug interactions involving other co-administered drugs are unlikely.
Introduction
Cediranib (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline; RECENTIN™; AZD2171)) ( Fig. 1 ) is a highly potent vascular endothelial growth factor (VEGF) inhibitor, with activity against all three VEGF receptor tyrosine kinases, and stem cell factor receptor (KIT). It is currently in Phase III clinical trials for the treatment of colorectal cancer (CRC) and recurrent glioblastoma. VEGF is involved in the regulation of key processes throughout the angiogenic cascade, and overproduction of VEGF in tumours facilitates tumour progression by stimulating angiogenesis and increasing vascular permeability. Inhibition of VEGF receptor tyrosine kinases stabilizes the progression of tumours by disrupting tumour-induced angiogenesis (Kim et al., 1993) .
Pre-clinical studies have shown that cediranib prevents VEGF-induced angiogenesis in vivo
and inhibits the growth of established human tumour xenografts in athmic mice in a dose-dependent manner (Wedge et al., 2005) . In the clinic, cediranib has exhibited activity in patients with advanced CRC and recurrent glioblastoma (Batchelor et al., 2007; Drevs et al., 2007; Chen et al., 2009 ).
To gain an understanding of the species differences in the disposition of cediranib and pre-clinical coverage of human metabolites, the hepatic metabolism of [ 14 C]-cediranib was investigated in liver preparations from preclinical species and human. The in vitro metabolic profiles and identity of cediranib metabolites were assessed and a proposed metabolic pathway suggested. The identity of the hepatic human Phase I and II enzymes involved in the oxidation and conjugation of cediranib were confirmed and are reported here.
This article has not been copyedited and formatted. The final version may differ from this version. For incubations with individual recombinant UGT enzymes, the incubations mixtures contained the same components, except that a final protein concentration of 0.25 mg UGT protein/mL was used. In addition, following a 60-min incubation at 37°C, aliquots were removed into an equal volume of 0.05% formic acid in ethanol. determined prior to injection onto the HPLC system. To ensure the system suitability, the recovery of radioactivity from the column was evaluated by comparing the radioactive content (determined by liquid scintillation counting) of the post-column eluent to the precolumn eluent. No loss of radioactivity on the column was found for any of the incubated samples.
For the UGT and FMO phenotyping experiments and Phase II microsomal incubate samples, a shorter HPLC gradient was used. [ 14 C]-cediranib and its metabolites were separated on a Polaris C18-A column (4.6 X 150 mm, 5 µm, Varian, Yarnton, UK) using either Jasco PU-1580 Intelligent (Jasco (UK), Great Dunmow, UK) or Agilent 1200 Series (Agilent Technologies UK Ltd, Stockport, UK) HPLC pumps. The initial mobile phase consisted of 5% solvent B, which was maintained for 2 min, increased to 25% over a period of 4.5 min, further increased to 29% in 15.5 min, to 33% in 4 min, and finally to 95% in 1.5 min. This value was held for 4.5 min before returning to 5% solvent B for column equilibration for 4.9 min before the next injection.
[ 14 C]-acetaminophen and its metabolites were separated on an Eclipse XDB C18 column (4.6 X 150 mm, 5 µm; Agilent Technologies UK Ltd, Stockport, UK) using Agilent 1200
Series HPLC pumps (Stockport, UK) with a flow rate of 1 mL/min. The aqueous mobile phase (solvent A) consisted of ammonium acetate in deionised water (10 mM; pH 5.5) while the organic mobile phase (solvent B) consisted of methanol. The initial mobile phase consisted of 5% solvent B, which was maintained for 15 min and increased to 95% over a period of 1 min. This value was returned to 5% solvent B within a 1 min for column equilibration for 3 min before the next injection.
This article has not been copyedited and formatted. The final version may differ from this version. Intelligent HPLC pumps (Jasco (UK), Great Dunmow, UK) with a flow rate of 1 mL/min.
The aqueous mobile phase (solvent A) consisted of ammonium acetate in deionised water (10 mM; pH 5.5) while the organic mobile phase (solvent B) consisted of methanol. The initial mobile phase consisted of 10% solvent B, which was increased to 17% over a period of 7 min, further increased to 29% in 2min, to 55% in 10 min and finally to 70% in 6 min. This value was returned to 10% solvent B within a 5 min for column equilibration for 5 min before the next injection. Figure 2A ; Table 1 ). Minor components included metabolites M1, M2 and M4. The formation of M3 as well as M1 and M4 were not inhibited in the presence of the non-selective CYP450 chemical inhibitor, 1-ABT ( Figure 2B ).
Metabolite identification by HPLC-MS
Consistent with the findings in human hepatocyte suspensions, [ 14 C]-cediranib was metabolised to these 4 components as well as to two further minor metabolites M5 and M7, in human hepatocyte cultures ( Figure 2C ; Table 1 ). With the exception of metabolite M3, all other metabolites detected in human hepatocytes were also observed in either rat and/or cynomolgus monkey hepatocyte cultures (Figure 3 ). Unlike human, M4 was the major metabolite in both rat and cynomolgus hepatocyte incubations and accounted for 30 and 9%, respectively, of total chromatogram radioactivity. Metabolites M8, M10 and M11 were detected in rat and cynomolgus monkey hepatocyte samples but not in human hepatocytes, whilst metabolites M6 and M10 were detected only in cynomolgus monkey hepatocytes (Table 1 ). The mass spectral data for cediranib and its metabolites are summarised in 
). The proton NMR chemical shifts and coupling constants of a bio-synthesised standard of metabolite M3 are included in Table 3 . and 342 respectively), this suggested that oxidations had occurred on this group, resulting in the formation of the carboxylic acid M7 (Table 2) .
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Discussion
The present study was undertaken to elucidate the biotransformation pathways and identify the enzymes involved in the in vitro metabolism of cediranib. It has been demonstrated that the in vitro metabolism of cediranib proceeds predominantly via non-CYP450 enzymes, with the UGT and FMO enzymes playing a major role.
In vitro metabolism studies have shown that cediranib was metabolised to at least 11 components in hepatic proteins from human, rat and cynomolgus monkey. A summary of the proposed metabolic pathway of [ 14 C]-cediranib is highlighted in Figure 6 .
Incubations with hepatic in vitro systems have highlighted that marked species differences in the N + -glucuronidation of cediranib was observed. The formation of the pyrrolidine N + -glucuronide metabolite (M3) was only produced in human and was not detected in the other species tested. This finding was supported by previous studies where quaternary N-glucuronidation of cyclic tertiary amines were shown to exhibit distinct species differences, with a general trend that only human and higher primates have the capability of catalysing such reactions (Chaudhuri et al., 1976; Fisher et al., 1980; Delbressine et al., 1992; Chiu & Huskey, 1998) . These studies have shown that several cyclic tertiary amine- Dawley rats (unpublished data). Additional data to be published at a later date will support the conclusion that M3 is a major metabolite in human and should be considered in this context.
The enzyme catalysing the N + -glucuronidation of cediranib was shown using recombinant proteins to be human UGT1A4. This observation is consistent with previous studies confirming that N + -glucuronidation of cyclic tertiary amines usually proceeds via UGT1A4 (Green et al., 1995; Green et al., 1998; Green & Tephly, 1996; 1998; Kubota et al., 2007) .
Information on the interspecies variation in the expression of this enzyme is limited, although it is well established that in the rat, a pseudo-gene is present in the UGT1 gene complex that encodes for an incomplete UGT1A4 protein, leaving the rat without a functional UGT1A4 cediranib disposition in vivo and impact on an individual's response to cediranib treatment remains to be assessed, given that functional investigations of UGT1A4 polymorphisms to date have been limited to in vitro systems. In addition, it has also been suggested that the effects of these functional polymorphisms may be dependent on the xenobiotic administered (Mori et al., 2005) .
In this study, the human FMO enzymes were shown to be primarily involved in the N-oxidation of cediranib to metabolite M4. Amongst the FMO enzymes tested, only human FMO1 and FMO3 were able to catalyse this reaction in vitro, with FMO1 being most efficient in catalysing this reaction. Although FMO1 is the most prominent isoform in adult kidney, its expression is very low in adult liver, with FMO3 being the major isoform in this tissue (Cashman & Zhang, 2006) . Based on the kinetic parameters and absolute levels of each enzyme, it is conceivable that in vivo, both enzymes may be involved to a similar extent in the N-oxidation of cediranib. A role for the CYP450 enzymes in the formation of this metabolite was excluded, due to a lack of significant inhibition of cediranib N-oxide formation by 1-ABT.
The human enzyme(s) responsible for the metabolism of cediranib to metabolite M2 were CYP450 enzymes. As for metabolite M1, the enzymes involved in its formation are unknown and have yet to be determined. However, it is clear that CYP450 enzymes do not play a role, given the lack of inhibition of metabolite formation in the presence of 1-ABT.
Based on the structure of cediranib, a possible role for aldehyde oxidase may exist (Beedham, 2001 ). Whilst no metabolism of cediranib was observed following incubation with human cytosolic fractions, it should be noted that this may be due to the instability of aldehyde oxidase upon preparation and storage of the human hepatic tissue (Lang & Kalgutkar, 2003) .
This article has not been copyedited and formatted. The final version may differ from this version. For the formation of metabolite M11, which was only formed in rat and cynomolgus monkey, a potential mechanism would involve the hydroxylation of the methylene group adjacent to the pyrrolidine nitrogen, followed by the intermediate formation of the aldehyde through N-dealkylation, which would then be rapidly oxidised to the carboxylic acid M11.
In conclusion, the present study has shown that the major biotransformation pathways of in humans were also detected in rat and cynomolgus monkey. As the metabolism of cediranib proceeds via conjugative and non-CYP450 oxidative pathways, it is predicted that cediranib may be less prone to potential drug-drug interactions from other co-administered xenobiotics. The FMO enzymes are not readily inhibited or induced by xenobiotics (Cashman & Zhang, 2006 , Mitchell, 2008 and the magnitude of UGT-based drug interactions is significantly less when compared to CYP450-mediated interactions (Williams et al., 2004; Kiang et al., 2005) .
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